查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916510

全球血漿分離市場：市場規模、佔有率、成長率、產業分析、按類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Plasma Fractionation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 202 Pages | 商品交期: 請詢問到貨日

價格

血漿分離市場的成長驅動因素

全球血漿分離市場是生物製藥產業的重要組成部分，它能夠將人類血漿分離成治療性蛋白，例如免疫球蛋白、白蛋白、凝血因子和蛋白酶抑制劑。這些血漿衍生產品對於治療免疫缺陷疾病、出血性疾病、代謝性疾病、神經系統疾病和重症監護併發症至關重要。慢性病和罕見病患疾病的持續上升，以及血漿採集基礎設施的擴展，正在推動全球市場需求的成長。

血漿分離市場規模及價值

根據2025年市場報告，2025年全球血漿分離市場價值為402.7億美元。預計到2026年，該市場將增長至435.5億美元，主要驅動因素包括血漿捐獻量的增加、免疫球蛋白療法需求的增長以及主要生產商擴大血漿分離能力。在長期預測期內，預計到2034年，該市場將達到872億美元，反映出多個治療領域對血漿衍生藥物的強勁需求。受醫療保健支出成長和血漿生物製劑監管審批不斷增加的推動，預計2026年至2034年，該市場將以9.10%的複合年增長率成長。

市場成長驅動因素

主要成長驅動因素包括免疫缺陷、自體免疫疾病以及罕見遺傳性出血性疾病（如血友病A、血友病B和血管性血友病）盛行率的上升。對於許多此類疾病，血漿衍生療法仍然是主要治療選擇，從而支撐了對血漿分離產品的穩定需求。此外，HIV感染、原發性免疫缺陷和慢性肝病盛行率的上升也促進了免疫球蛋白和白蛋白消耗量的增加。

政府對血漿衍生藥物生產的支持進一步推動了市場成長。多個監管機構已將血漿療法認定為基本藥物，鼓勵各國實施國家血漿自給自足計畫並投資建立國內血漿分離產能。增加血液服務資金、放寬血漿使用管制以及公私合作正在改善血漿供應並加強生產管道。

市場趨勢與技術進步

血漿分離技術的進步正在提高生產效率、產量和蛋白質純度。自動化、改進的色譜系統和優化的分離技術使製造商能夠最大限度地提高每公升採集血漿的產量。新一代捐血者採集系統也正在提高捐血者安全性並縮短血漿採集時間，從而提高供應穩定性。

另一個新興趨勢是開發血漿蛋白衍生生物製劑和生物相似藥。製造商正在擴大臨床研究項目，以探索免疫球蛋白和白蛋白在神經系統疾病、肝病和發炎性疾病中的新治療應用。生物製藥公司和蛋白質技術供應商之間的策略聯盟正在加速以血漿蛋白為關鍵原料的生物製劑的開發。

市場限制與挑戰

儘管需求強勁，血漿分離市場仍面臨諸多挑戰，包括生產成本高昂、監管合規要求嚴格以及對血漿供應的依賴。分離設施需要高度專業化的設備、經過驗證的純化流程以及嚴格的病毒滅活方案，這些都會推高營運成本。血漿衍生產品的監管審批通常涉及漫長的臨床試驗和生產流程評估，從而延緩了市場准入。

重組療法的日益普及帶來了競爭壓力。重組凝血因子和生物製劑具有感染風險低、半衰期長的優勢，因此在預防性治療方案的應用日益廣泛。這些替代療法正在逐步減少某些患者族群對血漿衍生凝血因子的依賴。

由於血漿完全來自人類捐贈者，血漿供應鏈的穩定性仍然是一個挑戰。捐贈者招募、物流或監管政策方面的中斷會直接影響生產能力和產品供應。

依產品劃分的細分市場分析

依產品劃分，市場包括免疫球蛋白、白蛋白、凝血因子和蛋白酶抑制劑。預計到 2026 年，免疫球蛋白細分市場將以 53.76% 的市場佔有率領先，這主要得益於其在原發性和繼發性免疫缺陷以及自體免疫疾病中的應用日益廣泛。靜脈注射免疫球蛋白 (IVIG) 和皮下注射免疫球蛋白 (SCIG) 製劑的監管審批不斷增加，正在推動其臨床應用。

白蛋白細分市場佔據第二大市場佔有率，這主要得益於其在肝病、重症監護、膿毒症和低白蛋白血症等領域的廣泛應用。由於出血性疾病的持續流行，凝血因子市場正經歷強勁成長，尤其是在新興市場，這些市場獲得重組替代產品的途徑仍然有限。蛋白酶抑​​制劑在治療感染性和發炎性疾病方面正逐漸獲得一定的應用。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要公司的血漿分離能力
  • 主要國家的血漿採集中心數量
  • 主要國家的血漿分離成本構成
  • 各地區的血漿分離處理量分佈
  • 主要慢性病盛行率適應症）：依主要國家劃分
  • 血漿分離製品價格分析：依主要國家劃分
  • 監理狀況：依主要國家劃分
  • 血漿採集技術：概述
  • 產品線分析：依主要公司劃分
  • 關鍵趨勢：併購、合作等
  • 新冠疫情對市場的影響

第五章 全球血漿分離市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品劃分
    • 白蛋白
    • 免疫球蛋白
      • 靜脈注射免疫球蛋白
      • 皮下注射免疫球蛋白
    • 凝血因子
      • 因子IX
      • 因子 VIII
      • 凝血酶原複合物濃縮物
      • 纖維蛋白原濃縮物
      • 其他
    • 蛋白酶抑​​製劑
    • 其他
  • 市場分析、洞察與預測：依應用領域劃分
    • 免疫學和神經病學
    • 血液學
    • 重症監護
    • 肺病學
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 臨床實驗室
    • 其他
  • 市場分析、洞察與預測：按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美血漿分離市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲血漿分離市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區血漿分離市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲血漿分離市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲血漿分離市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南亞國家非洲
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • CSL Behring (CSL)
    • Grifols, S.A
    • 武田藥品工業株式會社
    • Kedrion S.p.A
    • Octapharma
    • ADMA Biologics, Inc.
    • Sartorius AG
    • LFB
Product Code: FBI101614

Growth Factors of plasma fractionation Market

The global plasma fractionation market is a vital component of the biopharmaceutical industry, enabling the separation of human plasma into therapeutic proteins such as immunoglobulins, albumin, coagulation factors, and protease inhibitors. These plasma-derived products are essential for treating immunodeficiency disorders, bleeding disorders, metabolic diseases, neurological conditions, and critical care complications. Continuous growth in chronic and rare disease prevalence, along with expansion of plasma collection infrastructure, is strengthening market demand worldwide.

Plasma Fractionation Market Size and Market Value

According to the 2025 market report, the global plasma fractionation market size was valued at USD 40.27 billion in 2025. The market is projected to grow to USD 43.55 billion in 2026, supported by increasing plasma donation volumes, growing demand for immunoglobulin therapies, and expansion of fractionation capacity by major manufacturers. Over the long-term forecast period, the market is expected to reach a market value of USD 87.20 billion by 2034, reflecting strong demand for plasma-derived medicinal products across multiple therapeutic areas. The market is projected to grow at a CAGR of 9.10% from 2026 to 2034, driven by rising healthcare spending and increasing regulatory approvals of plasma-based biologics.

Market Drivers Supporting Growth

A major growth driver is the increasing prevalence of immunodeficiency disorders, autoimmune diseases, and rare genetic bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease. Plasma-derived therapies remain the primary treatment option for many of these conditions, supporting consistent demand for fractionated products. Rising numbers of patients with HIV, primary immunodeficiency disorders, and chronic liver disease are also contributing to higher immunoglobulin and albumin consumption.

Government support for plasma-derived medicinal product manufacturing is further strengthening market growth. Several regulatory bodies recognize plasma therapies as essential medicines, encouraging national plasma self-sufficiency programs and investment in domestic fractionation capacity. Increasing funding for blood services, regulatory relaxation for plasma usage, and public-private partnerships are improving plasma availability and strengthening production pipelines.

Market Trends and Technology Advancements

Technological advancements in plasma fractionation are improving production efficiency, yield, and protein purity. Automation, improved chromatography systems, and optimized separation techniques are enabling manufacturers to maximize output from each liter of collected plasma. Next-generation donor collection systems are also improving donor safety and reducing plasma collection time, enhancing supply stability.

Another emerging trend is the development of biological products and biosimilars derived from plasma proteins. Manufacturers are expanding clinical research programs to explore new therapeutic indications for immunoglobulins and albumin in neurology, liver disease, and inflammatory disorders. Strategic collaborations between biopharmaceutical companies and protein technology providers are accelerating biologics development using plasma proteins as critical raw materials.

Market Restraints and Challenges

Despite strong demand, the plasma fractionation market faces challenges related to high production costs, strict regulatory compliance, and plasma supply dependency. Fractionation facilities require highly specialized equipment, validated purification processes, and strict viral inactivation protocols, which increase operational expenses. Regulatory approvals for plasma-derived products often involve lengthy clinical and manufacturing evaluations, delaying market entry.

The increasing adoption of recombinant therapies presents competitive pressure. Recombinant clotting factors and biologics offer reduced infection risk and longer half-life, leading to increased use in prophylactic treatment regimens. These alternatives are gradually reducing dependence on plasma-derived coagulation factors in certain patient groups.

Plasma supply chain stability also remains a challenge, as plasma is sourced exclusively from human donors. Any disruption in donor recruitment, logistics, or regulatory policies can directly impact manufacturing capacity and product availability.

Segmentation Analysis by Product

By product, the market includes immunoglobulins, albumin, coagulation factors, protease inhibitors, and others. The immunoglobulin segment dominated the market with a 53.76% share in 2026, driven by rising use in primary and secondary immunodeficiency disorders and autoimmune diseases. Increasing regulatory approvals for both IVIG and SCIG formulations are strengthening clinical adoption.

The albumin segment held the second-largest share, supported by growing use in liver diseases, critical care, sepsis, and hypoalbuminemia. Coagulation factors are witnessing strong growth due to the continued prevalence of bleeding disorders, particularly in emerging markets where access to recombinant alternatives remains limited. Protease inhibitors are gaining moderate traction in infectious disease and inflammatory disorder treatments.

Segmentation by Application and End User

By application, immunology and neurology accounted for the largest market share, estimated at 70.50% in 2026, driven by expanding indications for immunoglobulin therapies in autoimmune neuropathies and immune disorders. Hematology represents the second-largest segment, supported by hemophilia management programs and clotting factor demand. Critical care applications are rising due to increasing trauma cases and surgical interventions.

By end user, hospitals and clinics dominated the market with an estimated 86.67% share in 2026, supported by high inpatient use of plasma therapies and centralized treatment protocols. Clinical research laboratories are growing steadily due to expanding plasma-based drug development programs.

Regional Outlook

North America dominated the plasma fractionation market with a market size of USD 24.50 billion in 2025 and USD 26.57 billion in 2026, supported by extensive plasma collection networks, strong reimbursement systems, and high therapeutic adoption. Europe held the second-largest share in 2026, driven by increasing plasma self-sufficiency initiatives and expansion of fractionation facilities.

Asia Pacific is emerging as a high-growth region due to expanding healthcare infrastructure, rising chronic disease prevalence, and increasing domestic plasma manufacturing investments in China, Japan, and India. Latin America and the Middle East & Africa are witnessing gradual growth supported by government healthcare investments and rising demand for immunoglobulin therapies.

Competitive Landscape

The plasma fractionation market is highly consolidated, with major players including CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion, ADMA Biologics, Sartorius AG, and LFB. Companies are actively expanding plasma collection centers, investing in fractionation capacity, and launching new plasma-derived products. Strategic acquisitions, long-term plasma supply agreements, and facility expansions remain central to competitive strategies across global markets.

Conclusion

The global plasma fractionation market is positioned for strong and sustained expansion, supported by rising prevalence of immunodeficiency, autoimmune, and bleeding disorders, along with continuous growth in demand for immunoglobulins, albumin, and coagulation factors. With the market valued at USD 40.27 billion in 2025, projected to reach USD 43.55 billion in 2026 and further expand to USD 87.20 billion by 2034, the industry reflects robust long-term growth potential. Ongoing investments in plasma collection networks, expansion of fractionation capacity, technological advancements in purification and automation, and increasing regulatory approvals for plasma-derived therapies are strengthening market penetration across hospitals and specialty treatment centers. Although challenges such as high production costs, regulatory complexity, and competition from recombinant therapies persist, rising healthcare spending, government support for plasma self-sufficiency programs, and expanding clinical applications of plasma-derived products are expected to continue driving market momentum globally.

Segmentation By Product

  • Albumin
  • Immunoglobulin
    • Intravenous Immunoglobulin
    • Subcutaneous Immunoglobulin
  • Coagulation Factors
    • Factor IX
    • Factor VIII
    • Prothrombin Complex Concentrates
    • Fibrinogen Concentrates
    • Others
  • Protease Inhibitors
  • Others

By Application

  • Immunology & Neurology
  • Hematology
  • Critical Care
  • Pulmonology
  • Others

By End-user

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Others

By Region

  • North America (By Product, Application, End-user, and Country)
  • U.S. (By Product)
  • Canada (By Product)
  • Europe (By Product, Application, End-user, and Country/Sub-Region)
  • U.K. (By Product)
  • Germany (By Product)
  • France (By Product)
  • Italy (By Product)
  • Spain (By Product)
  • Scandinavia (By Product)
  • Rest of Europe (By Product)
  • Asia Pacific (By Product, Application, End-user, and Country/Sub-Region)
  • China (By Product)
  • Japan (By Product)
  • India (By Product)
  • Australia (By Product)
  • Southeast Asia (By Product)
  • Rest of Asia Pacific (By Product)
  • Latin America (By Product, Application, End-user, and Country/Sub-Region)
  • Brazil (By Product)
  • Mexico (By Product)
  • Rest of Latin America (By Product)
  • Middle East & Africa (By Product, Application, End-user, and Country/Sub-Region)
  • GCC (By Product)
  • South Africa (By Product)
  • Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Plasma Fractionation Capacity, By Key Players
  • 4.2. Number of Plasma Collection Centers, By Key Countries
  • 4.3. Cost Breakdown of Plasma Fractionation, By Key Countries
  • 4.4. Regional Distribution of Plasma Fractionation Throughput
  • 4.5. Prevalence of Chronic Diseases (Key Indications), By Key Countries
  • 4.6. Pricing Analysis, Plasma Fractionated Products, By Key Countries
  • 4.7. Regulatory Scenario, By Key Countries
  • 4.8. Overview : Plasma Collection Technologies
  • 4.9. Pipeline Analysis, By Key Companies
  • 4.10. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.11. Impact of COVID-19 on the Market

5. Global Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Albumin
    • 5.1.2. Immunoglobulin
      • 5.1.2.1. Intravenous Immunoglobulin
      • 5.1.2.2. Subcutaneous Immunoglobulin
    • 5.1.3. Coagulation Factors
      • 5.1.3.1. Factor IX
      • 5.1.3.2. Factor VIII
      • 5.1.3.3. Prothrombin Complex Concentrates
      • 5.1.3.4. Fibrinogen concentrates
      • 5.1.3.5. Others
    • 5.1.4. Protease Inhibitors
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Immunology & Neurology
    • 5.2.2. Hematology
    • 5.2.3. Critical Care
    • 5.2.4. Pulmonology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Clinical Research Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Albumin
    • 6.1.2. Immunoglobulin
      • 6.1.2.1. Intravenous Immunoglobulin
      • 6.1.2.2. Subcutaneous Immunoglobulin
    • 6.1.3. Coagulation Factors
      • 6.1.3.1. Factor IX
      • 6.1.3.2. Factor VIII
      • 6.1.3.3. Prothrombin Complex Concentrates
      • 6.1.3.4. Fibrinogen concentrates
      • 6.1.3.5. Others
    • 6.1.4. Protease Inhibitors
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Immunology & Neurology
    • 6.2.2. Hematology
    • 6.2.3. Critical Care
    • 6.2.4. Pulmonology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Clinical Research Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Product
    • 6.4.2. Canada
      • 6.4.2.1. By Product

7. Europe Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Albumin
    • 7.1.2. Immunoglobulin
      • 7.1.2.1. Intravenous Immunoglobulin
      • 7.1.2.2. Subcutaneous Immunoglobulin
    • 7.1.3. Coagulation Factors
      • 7.1.3.1. Factor IX
      • 7.1.3.2. Factor VIII
      • 7.1.3.3. Prothrombin Complex Concentrates
      • 7.1.3.4. Fibrinogen concentrates
      • 7.1.3.5. Others
    • 7.1.4. Protease Inhibitors
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Immunology & Neurology
    • 7.2.2. Hematology
    • 7.2.3. Critical Care
    • 7.2.4. Pulmonology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Clinical Research Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
      • 7.4.1.1. By Product
    • 7.4.2. Germany
      • 7.4.2.1. By Product
    • 7.4.3. France
      • 7.4.3.1. By Product
    • 7.4.4. Spain
      • 7.4.4.1. By Product
    • 7.4.5. Italy
      • 7.4.5.1. By Product
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Product
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Product

8. Asia Pacific Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Albumin
    • 8.1.2. Immunoglobulin
      • 8.1.2.1. Intravenous Immunoglobulin
      • 8.1.2.2. Subcutaneous Immunoglobulin
    • 8.1.3. Coagulation Factors
      • 8.1.3.1. Factor IX
      • 8.1.3.2. Factor VIII
      • 8.1.3.3. Prothrombin Complex Concentrates
      • 8.1.3.4. Fibrinogen concentrates
      • 8.1.3.5. Others
    • 8.1.4. Protease Inhibitors
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Immunology & Neurology
    • 8.2.2. Hematology
    • 8.2.3. Critical Care
    • 8.2.4. Pulmonology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Clinical Research Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
      • 8.4.1.1. By Product
    • 8.4.2. China
      • 8.4.2.1. By Product
    • 8.4.3. India
      • 8.4.3.1. By Product
    • 8.4.4. Australia
      • 8.4.4.1. By Product
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Product
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Product

9. Latin America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Albumin
    • 9.1.2. Immunoglobulin
      • 9.1.2.1. Intravenous Immunoglobulin
      • 9.1.2.2. Subcutaneous Immunoglobulin
    • 9.1.3. Coagulation Factors
      • 9.1.3.1. Factor IX
      • 9.1.3.2. Factor VIII
      • 9.1.3.3. Prothrombin Complex Concentrates
      • 9.1.3.4. Fibrinogen concentrates
      • 9.1.3.5. Others
    • 9.1.4. Protease Inhibitors
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Immunology & Neurology
    • 9.2.2. Hematology
    • 9.2.3. Critical Care
    • 9.2.4. Pulmonology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Clinical Research Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
      • 9.4.1.1. By Product
    • 9.4.2. Mexico
      • 9.4.2.1. By Product
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Product

10. Middle East & Africa Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Albumin
    • 10.1.2. Immunoglobulin
      • 10.1.2.1. Intravenous Immunoglobulin
      • 10.1.2.2. Subcutaneous Immunoglobulin
    • 10.1.3. Coagulation Factors
      • 10.1.3.1. Factor IX
      • 10.1.3.2. Factor VIII
      • 10.1.3.3. Prothrombin Complex Concentrates
      • 10.1.3.4. Fibrinogen concentrates
      • 10.1.3.5. Others
    • 10.1.4. Protease Inhibitors
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Immunology & Neurology
    • 10.2.2. Hematology
    • 10.2.3. Critical Care
    • 10.2.4. Pulmonology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Clinical Research Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
      • 10.4.1.1. By Product
    • 10.4.2. South Africa
      • 10.4.2.1. By Product
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Product

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. CSL Behring (CSL)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Grifols, S.A
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Takeda Pharmaceutical Company Limited
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Kedrion S.p.A
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Octapharma
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. ADMA Biologics, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sartorius AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. LFB
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 3: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 4: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 5: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 6: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 9: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 10: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 11: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 12: North America Plasma Fractionation Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Canada Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 16: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 17: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 18: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 20: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Germany Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: France Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Italy Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 25: Spain Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Scandinavia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 27: Rest of Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 28: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 29: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 30: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 31: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 32: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 33: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 35: Japan Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 36: India Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 37: Australia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Southeast Asia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 39: Rest of Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 40: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 41: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 42: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 43: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 45: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Brazil Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 47: Mexico Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 48: Rest of Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2033
  • Table 49: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 50: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 51: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 52: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 53: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 54: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 55: GCC Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 56: South Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 57: Rest of Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034

List of Figures

  • Figure 1: Global Plasma Fractionation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Plasma Fractionation Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Plasma Fractionation Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Plasma Fractionation Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Plasma Fractionation Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 8: North America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 10: North America Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 12: North America Plasma Fractionation Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Plasma Fractionation Market Value Share (%), By Country, 2025
  • Figure 14: Europe Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 16: Europe Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 18: Europe Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Plasma Fractionation Market Value (USD billion),by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Plasma Fractionation Market Share (%), By Company, 2025